the BIRDIE trial
Phase 1
- Conditions
- Severe asthmaTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
- Registration Number
- CTIS2023-505839-12-01
- Lead Sponsor
- Sint Franciscus Vlietland Groep Stichting
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 114
Inclusion Criteria
Severe asthma as primary indication for treatment with mepolizumab (one dose every 4 weeks) or dupilumab (one dose every 2 weeks) for the last 6 months., Stable asthma (an ACQ <1.5 and no severe asthma exacerbations) for at least 6 months., Sufficient understanding of the Dutch language
Exclusion Criteria
Treatment with maintenance OCS, defined as treatment with OCS during 14 or more subsequent days, in the last 6 months, Treatment with immunosuppressants (other than mepolizumab, dupilumab or corticosteroids) in the last 6 months, Treatment with, or switching between, other biologics than the drug of interest in the 6 months before inclusion., Pulmonary disease(s) other than asthma (including EGPA), Pregnancy
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method